Blog Examines Why PrEP For MSM Not More Widely Adopted

The Center for Global Health Policy’s “Science Speaks” blog examines the use of daily oral pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection among men who have sex with men (MSM). “…Of all the recent advancements that have been shown to be effective in preventing HIV, daily oral pre-exposure prophylaxis (PrEP) has been shown to be the most efficacious prevention method for men who have sex with men, after condoms. The landmark iPrEx trial demonstrated 41 percent efficacy among men who have sex with men and transgender women with a regimen that includes Truvada…” However, “only the U.S. has approved the use of daily oral Truvada PrEP for men who have sex with men and others at risk, but no other country that participated in iPrEx, including Thailand, Peru, Brazil, and South Africa, has followed…” (2/4).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.